Cocaine toxicity is a widespread problem in the United States, responsible for over half a million emergency department visits a year. There is currently no FDA-approved pharmacotherapy to directly treat cocaine toxicity. To this end, we have developed a mutant bacterial cocaine esterase (DM-CocE), which has been previously shown to rapidly hydrolyze cocaine into inert metabolites preventing and reversing toxicity with limited immunogenic potential. Herein we describe the ability of DM-CocE to hydrolyze the active cocaine metabolites norcocaine and cocaethylene, and its inability to hydrolyze benzoylecgonine. DMCocE hydrolyzes norcocaine and cocaethylene with 58% and 45% of its catalytic efficiency for cocaine in vitro as measured by a spectrophotometric assay. We have developed a mass spectrometry method to simultaneously detect cocaine, benzoylecgonine, norcocaine and ecgonine methyl ester to quantify the effect of DM-CocE on normal cocaine metabolism in vivo.
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Introduction
Cocaine is an addictive alkaloid derived from leaves of the South American shrub Erythroxylon coca. In the United States, over 1.5 million people use cocaine (Substance Abuse and Mental Health Services Administration, 2010) resulting in more than 500,000 emergency room visits each year (US Department of Health and Human Services). Although the addictive effects of cocaine are caused by cocaine's blockade of dopamine transporters in the brain, cocaine's toxicity is influenced by the blockade of norepinephrine transporters, effectively increasing both central and peripheral norepinephrine levels. The blockade of peripheral sodium channels amplifies the cardiovascular effects of cocaine including coronary vasospasm, increased heart rate, hypertension and ventricular arrhythmia (Freye and Levy, 2009; Schrank, 1992) . In addition to cardiac symptoms, the hallmarks of cocaine toxicity also include hyperthermia, convulsions, seizures, and psychosis (Schrank, 1992) .
Because cocaine acts on several targets to cause a wide range of symptoms, it has been difficult to develop a pharmacotherapy to treat cocaine toxicity, and there is currently no FDA-approved therapy for this indication. Emergency personnel are limited to treating the symptoms of cocaine toxicity only.
Although cocaine causes much of the observed toxicities, it is quickly metabolized, with a half-life of about 1-2 hours in humans, into compounds that also have strong physiological effects. The most abundant metabolite (40-50%), benzoylecgonine, is produced by hydrolysis of the methyl ester of cocaine by human liver carboxylesterase-1 (Dean et al., 1991) .
Benzoylecgonine is inactive at monoamine transporters; however, it has some vasoconstrictive effects possibly mediated through interactions with Ca 2+ channels (Madden et al., 1995) .
Benzoylecgonine (t 1/2 =7 hours) is the urinary metabolite measured in drug screens and may be the cause of latent chest pain associated with cocaine use.
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When alcohol is co-abused with cocaine, cocaethylene is also formed by human liver carboxylesterase-1 through a transesterification reaction with alcohol. This reaction decreases the hydrolysis of cocaine to benzoylecgonine. Cocaethylene has similar properties to the parent cocaine molecule. It is known to increase striatal dopamine concentrations in vivo (Iyer et al., 1995) and inhibit dopamine uptake in ex vivo assays (Jatlow et al., 1991) . Behavioral studies have demonstrated that cocaethylene is more potent than cocaine at producing lethality, but less potent increasing locomotor activity and equipotent at producing convulsions (Katz et al., 1992) . Additionally, cocaethylene blocks cardiac sodium channels (Xu et al., 1994) and causes larger changes in blood pressure, oxygen saturation, cardiac output, and QT interval than cocaine (Wilson et al., 2001) . The increased potency of cocaethylene at cardiac sodium channels may explain the behavioral observation of increased potency in lethality assays.
Norcocaine is formed by demethylation of cocaine by CYP3A4 in liver microsomes (Kloss et al., 1983; Pellinen et al., 1994) and is only a small fraction of cocaine's metabolites.
However, norcocaine and its downstream products n-hydroxynorcocaine and norcocaine nitroxide, are hepatotoxic (Ndikum-Moffor et al., 1998; Thompson et al., 1979) . Furthermore, norcocaine blocks cardiac sodium channels in vitro (Crumb and Clarkson, 1992) and causes the same hemodynamic changes in vivo as cocaine (Mahlakaarto et al., 1998) .
The inactive metabolites, ecgonine methyl ester and benzoic acid, are formed by the serum enzyme butyrylcholinesterase which accounts for about 40% of cocaine's initial metabolism. The bacterial enzyme cocaine esterase (CocE) catalyzes this same reaction but with a rate nearly 1000 times faster than the endogenous enzyme (V max =2300 min -1 ) (Bresler et al., 2000; Cooper et al., 2006; Gao et al., 2009; Larsen et al., 2002; Turner et al., 2002) . CocE is a 65 kDa (130 kDa dimer ) alpha-beta serine hydrolase that was originally isolated from the Rhoddococcus sp. MB1 soil bacterium (Bresler et al., 2000; This article has not been copyedited and formatted. The final version may differ from this version. CocE (T172R and G173Q, while preserving the hydrolytic function of the enzyme (Gao et al., 2009; Narasimhan et al., 2010) . CocE is well-classified as a cocaine hydrolyzing molecule in buffer (Gao et al., 2009) and human plasma Cooper et al., 2006) ; however, these studies only examined cocaine levels after CocE addition. Because the cocaine metabolites described above contain the same hydrolyzable ester linkage as cocaine, we investigated the ability of CocE to hydrolyze these metabolites. We have employed both in vitro and in vivo studies as well as developed a high performance liquid chromatography-tandem mass spectrometry method (LC-MS/MS) to enable simultaneous quantification of cocaine, ecgonine methyl ester, benzoylecgonine and norcocaine. By investigating these aspects, we will gain insight into the specificity of the stable DM-CocE mutant as a potential clinical therapy for cocaine toxicity.
Materials and Methods
Production and Purification of DM-Cocaine Esterase:
A pET24b plasmid containing DMCocE (65 kDa) was prepared as described previously (Gao et al., 2009; Narasimhan et al., 2010) and transformed into BL21 cells. Innoculum for a BioFlow 3000 bioreactor (New Brunswick, NJ) was produced by growing BL21 cells in a 250 mL culture of Terrific Broth (TB, Maniatis, BentonDickinson) containing Kanamycin (50 µg/mL) at 37°C until reaching log-phase growth (about 8 hours). The innoculum was added to 10 L of TB and Kanamycin (50 µg/mL) in the bioreactor and grown at 37°C until the culture reached an OD 600 of 5. Once the target turbidity was reached, the bioreactor was cooled to 18°C and then induced by adding IPTG for a final concentration of 1 mM. After 16 hours of induction, the culture was harvested by spinning down the broth at 4500 x g for 20 minutes. The resulting pellet was stored at -80°C.
Cell paste from 5 liters of a fermentor run was resuspended in phosphate buffered saline pH 7.4. The resuspended paste was passed through a French Press twice or three times to lyse This article has not been copyedited and formatted. The final version may differ from this version. The clarified lysate (500 mL) was passed onto a 450 mL Q Sepharose HP column (Qsepharose Fast Flow 17-0510-04, GE Healthcare, packed in-house) at room temperature. The column was washed with 1000 mL Q-buffer A followed by a gradient set to reach 50% Q-buffer B (20mM Hepes pH 8.0 + 1M NaCl) within 1000 mL. Flow-through and washes were saved for analysis. DM-CocE was eluted from the column using a gradient from 50 to 100% Q-buffer B over 5 column volumes (2250 mL). Fractions (25 mL) were collected at a flow rate of 10 mL/min.
DM-CocE was monitored by running 5 μl of each fraction on an 8% SDS PAGE Gel and staining with Coomassie Brilliant Blue stain according to established protocols.
Fractions from the first Q Sepharose HP separation were pooled (protein approximately 75% pure) and adjusted to 1M ammonium sulfate (final volume 525 mL).
Samples were applied to a 450 mL Phenyl-Sepharose column (Phenyl Sepharose 6 Fast Flow 17-0973-03,GE Healthcare, packed in-house) pre-equilibrated with PS-Buffer A (Buffer A:
50mM Na Phos, pH 7 + 1M ammonium sulfate). The column was washed with 1000 mL of PSBuffer A followed by an additional wash in the form of a linear gradient to reach 30% PS-Buffer B (Buffer B: 50mM Na Phos, pH 7) over two column volumes (~1000 mL). DM-CocE was eluted with 30% to 100% PS Buffer-B over 5 column volumes (2250 mL). Fractions (25 mL) were collected over the elution gradient. The presence and purity of DM-CocE were checked by running 5 μL of each fraction on an 8% SDS PAGE gel. Approximately 95% of the estimated DM-CocE protein was recovered and was 99% pure after Phenyl-Sepharose.
Fractions from the Phenyl-Sepharose column were pooled and extracted twice with Triton X-114 to remove endotoxin. The twice-extracted protein was then diluted with Q-buffer A This article has not been copyedited and formatted. The final version may differ from this version. coefficient was used to convert the change in absorbance over time to the change in concentration over time. Extinction coefficients (ε) for the metabolites were determined using the absorbance of these metabolites at 240 nm and Beer's Law (A=εbc). Our laboratory has determined these to be: norcocaine=8.7 L/mmol/cm, benzoylecgonine=7.5 L/mmol/cm, cocaethylene=11.6 L/mmol/cm. The rate of cocaine hydrolysis per mole of enzyme (K cat ) and the k m were determined using Prism software (GraphPad, San Diego) to fit the data to the following equation:
Metabolite Formation and Elimination: Male Sprague Dawley rats (300-350g) (Harlan Sprague Dawley, Indianapolis) were maintained in a temperature controlled environment with a 12-hour light cycle, beginning at 7AM. Rats were given ad libitum access to food and water, and were allowed to acclimate to the room for at least 5 days before surgery. Rats were This article has not been copyedited and formatted. The final version may differ from this version. implanted with 2 indwelling femoral catheters. Briefly, the rats were anesthetized with ketamine (90 mg/kg) and xylazine (10 mg/kg). Catheters were inserted into the femoral vein of both legs after the vein was manually separated from the femoral artery and nerve. Catheters were threaded under the skin and attached to stainless steel tubing that runs through a metal tether plate sutured to the back muscle. Animals were allowed to recover from the procedure for 5 days before use.
On the day of the experiment, rats were placed in 49 cm long x 23 cm wide x 21 cm high Plexiglas cages containing cob bedding. A long piece of catheter tubing was extended from the stainless steel tubing of the metal tether plate out of the cage so that rats could be infused, and blood could be drawn without direct handling. At time t=0, rats were given a 10 second bolus of 5.6 mg/kg cocaine (5.6 mg/mL) followed by a bolus of either DM-CocE (0.32 mg/kg, 0.32 mg/mL) or PBS at t=10 minutes. Blood was sampled (200 µL) at t= 2, 5, 9, 10.75, 12, 15, 20, 40 and 60 minutes, and immediately added to 5 µL of 500 mM EDTA plus 20 µL of 1M NaF to prevent coagulation and further cocaine hydrolysis, respectively. Plasma was separated from blood cells by centrifugation at 1500 rcf in a bench top microcentrifuge, flash frozen in liquid nitrogen, and stored at -80°C until preparation for mass spectrometry. at -80°C until sample preparation. A full series of calibration standards was prepared with every set of experimental samples. Calibration stocks (20 µL) were extracted with 68 µL ACN, 4 µL 1M NaF, and 2 µL of 2.5 µM of each deuterium-labeled norcocaine, cocaine, benzoylecgonine and ecgonine methyl ester as described above. Calibration standards were reconstituted to 100 µL resulting in final internal standard concentrations of 50 nM.
Quantification of cocaine metabolites by LC-MS/MS: Analysis was performed on a
Prominence HPLC system (Shimadzu, Kyoto, Japan) interfaced directly to the Turbo Ionspray source of an API 3000 triple quadrupole mass spectrometer (PE Sciex, Toronto, ON, Canada).
This article has not been copyedited and formatted. The final version may differ from this version. Separation was achieved with a Thermo Hypersil Gold column (50 x 2.1mm i.d., 1.9 µm packing) maintained at 45 ºC using a binary gradient and a flow rate of 0.45 mL/min. The flow was split approximately 1 to 3.5 so that 0.13 mL/min was directed into the ionization source.
Solvent A was 10 mM ammonium formate pH 4.6 and Solvent B was ACN. The gradient program was as follows: 2% B at 0 min, hold 2% B for 1 min, 18% B at 2 min, 40% B at 10 min, 100% B at 11 min, 2% B at 12 min, and re-equilibrate at 2% B for 3 min. Each analysis was completed in 15 minutes. Aliquots (4 µL) were injected onto the column and the sample tray was cooled to 10 ºC to prevent sample degradation.
Positive ions were generated in the source using purified air for the source gases under the following conditions and settings: Turbo ESI gas, 7.0 L/min; nebulizer (NEB) setting, 15; ion spray voltage (IS), 3000 V; source gas temperature (TEM), 400 ºC. Compound-specific ionization parameters were optimized for cocaine, each metabolite, and the internal standards as shown in Table 1 . Nitrogen was used as the curtain gas (CUR) at a setting of 12. Mass analysis was performed by single reaction monitoring (SRM) with 100 ms dwell times using the precursor-to-product ion pairs determined from the MS/MS spectra collected by direct infusion of authentic standards (Figure 1 ). Nitrogen served as the collision gas (CAD=12). The chromatogram was divided into three time segments so that individual periods contained a subset of one or two target compounds. The corresponding SRM transitions were scanned only during the time segments in which they eluted. Period 1 spanned the first 2 minutes, Period 2 covered the next 1.7 minutes, and Period 3 extended for the remainder of the chromatogram.
Precursor/product-ion pairs for the SRM transitions and their respective scan periods are listed in Table 2 . Analyst software (version 1.4.2; MDS Sciex, Toronto, ON, Canada) was used for instrument control, data acquisition, and quantitative analysis. Calibration curves were constructed from the standard samples. The ratios of the peak areas of the target compounds to the corresponding deuterium-labeled internal standards were plotted as a function of the This article has not been copyedited and formatted. The final version may differ from this version. analyte concentration normalized to the internal standard concentration. Calibration curves were generated using a least squares linear regression analysis with 1/x weighting, not including the origin. Even when higher concentrations of DM-CocE were assessed (100 ng/mL compared to 25 ng/mL), benzoylecgonine was not hydrolyzed according to Michaelis-Menten kinetics to any measurable level.
Results
Effect of DM-CocE on
This article has not been copyedited and formatted. The final version may differ from this version. Development of high performance liquid chromatography-tandem mass spectrometry assay: To expand on the spectrophotometric assay and to validate these findings in a physiological setting, we sought to monitor the elimination of cocaine and its metabolites in vivo. This required an assay that could simultaneously detect cocaine, ecgonine methyl ester, benzoylecgonine and norcocaine in a plasma matrix. A Thermo Hypersil Gold column with 1.9 µm particles and dimensions 50mm x 2.1mm i.d. provided the best combination of retention and resolution of cocaine and the three metabolites of interest (Figure 4 ). Ecgonine methyl ester was slightly retained on this column, and cocaine and norcocaine were nearly baseline-resolved. The LINAC™ technology (Loboda et al., 2000) incorporated into the collision cell prevents any cross talk from the small amount of overlap between the cocaine and norcocaine peaks thus allowing accurate quantification of these two compounds.
Chromatographic peaks were narrow and symmetrical with the exception of ecgonine methyl ester which displayed a slight amount of tailing. The MS scan dwell time was shortened from the instrument default of 300 mSec to 100 mSec in order to characterize the peaks more exactly. Furthermore, time segmentation was used to divide the chromatogram into three periods to reduce the number of SRM transitions that were monitored during each scan cycle.
Instead of continuously collecting data for all eight SRM transitions throughout the entire chromatogram, only those transitions corresponding to the compounds eluting during that time period were scanned. As a result of all these improvements, the final method was accurate and precise, with good linearity for all the target compounds ( Figure 5 ).
Effect of DM-CocE on cocaine metabolites in vivo:
Male Sprague Dawley rats were given a dose of 5.6 mg/kg cocaine at time t=0 and a dose of 0.32 mg/kg DM-CocE at time t=10 minutes.
This article has not been copyedited and formatted. The final version may differ from this version. Blood samples were taken over 60 minutes for analysis by LC-MS/MS. Cocaine, benzoylecgonine, ecgonine methyl ester and norcocaine were quantified simultaneously in each serum sample using the method developed for this study.
Cocaine produced an initial concentration of 7.1-27.1 µM in the rats. In the animals receiving only PBS vehicle at the 10 minute time point, the concentration of cocaine slowly fell over the 60 minute period due to slow natural hydrolysis. The majority of cocaine was converted into benzoylecgonine and ecgonine methyl ester, with norcocaine produced as a minor metabolite in the rats, as expected ( Figure 6 ). The natural metabolism of cocaine was significantly and predictably altered by the administration of DM-CocE 10 minutes after cocaine dosing. Cocaine was rapidly metabolized by DM-CocE to levels below the limit of quantification within 2 minutes after administration. The cocaine was immediately converted into ecgonine methyl ester and peak concentrations ranged from 9.1-11.4 µM at t=12 min. Consistent with the in vitro results, DM-CocE also eliminated the norcocaine that was formed before esterase administration. The concentration of norcocaine decreased from 10 nM at t=9 min to levels below the quantification limit of 3 nM at t=10:45, only seconds after the administration of DMCocE. Although DM-CocE did not hydrolyze benzoylecgonine in vitro, a rapid reduction then stabilization of benzoylecgonine concentration was observed in rats after DM-CocE administration.
Discussion
This work describes not only the ability of cocaine esterase to eliminate cocaine metabolites, but demonstrates the utility of simultaneous detection of the major cocaine metabolites. Our data show that although DM-CocE is an enzyme specific for cocaine, it can also hydrolyze the active cocaine metabolites norcocaine and cocaethylene but not benzoylecgonine. These data suggest several structure-function relationships between DMThis article has not been copyedited and formatted. The final version may differ from this version. It is possible that norcocaine, with a slightly more negative charge than cocaine, is not properly oriented in the enzyme active site pocket containing the negatively changed hydroxyl group of serine 117 that initiates the nucleophilic attack on the benzoyl ester linkage of cocaine .
Cocaethylene retains the same charge as the parent molecule and contains an additional methyl group. The larger molecular size of cocaethylene may decrease its capacity to bind to the active site of DM-CocE, most likely due to simple steric hindrance, thus decreasing its hydrolysis by DM-CocE.
No activity against benzoylecgonine was detected in our in vitro assay. This result was surprising, considering that compared to cocaine, benzoylecgonine is only slightly smaller and retains most of the charge properties. Loss of the methyl group exposes a hydroxyl group, which could create a small, negative charge that reduces binding, similar to norcocaine.
However, the in vivo data suggests that DM-CocE may be binding to benzoylecgonine, since there is a significant and rapid decrease in the concentration of benzoylecgonine after the addition of DM-CocE that persists for about 2 minutes, at which point the concentration stabilizes. This suggests that the lack of enzyme hydrolysis observed with DM-CocE and benzoylecgonine is most likely due to an inability to hydrolyze the molecule, not an inability to bind.
To further validate our in vitro results, we developed a LC-MS/MS method to simultaneously detect and quantify cocaine and its major metabolites. Most drug screening
This article has not been copyedited and formatted. The final version may differ from this version. assays include cocaine and at least one major metabolite, usually benzoylecgonine, and an increasing number of these screens are now performed using LC-MS/MS technology (Badawi et al., 2009; Dams et al., 2007; Shakleya et al., 2010; Wang et al., 2010) . While the methods have been well-documented (Badawi et al., 2009; Dams et al., 2007; Shakleya et al., 2010; Wang et al., 2010) , the goal of a screen is to incorporate as many compounds as possible into a single assay. Comprehensive screens may even require the use of expensive ultra performance liquid chromatography instrumentation (Badawi et al., 2009 ) to achieve sufficient resolution of all components. The study described in this report centers on the metabolism of a single drug (cocaine), so a simple, targeted method for the analysis of cocaine, norcocaine, benzoylecgonine, and ecgonine methyl ester was developed.
Because of the structural similarities of these compounds, the product ion spectra generated in MS/MS are also very similar. Many overlapping fragment ions were observed, though the relative abundances varied from compound to compound. As a result, good chromatographic separation is required for accurate quantitative analysis since these compounds could not be separated entirely by the mass spectrometer. Traditional microbore HPLC columns (3 µm, 150mm x 2.0mm i.d.) containing stationary phases such as C18 and phenyl hexyl in combination with H 2 O/ACN/formic acid solvent gradients did not resolve cocaine and norcocaine. Furthermore, ecgonine methyl ester, the most polar metabolite, eluted in or very near to the void volume of these columns, and was often obscured by non-retained salts and low molecular weight contaminants. Ecgonine methyl ester was also not strongly retained on columns that combine polar end capping with hydrophobic alkyl chains to provide mixedmode retention mechanisms (e.g., Phenomenex Synergi Hydro RP). Peak shapes were significantly improved by the substitution of 10 mM ammonium formate pH 4.6 for 0.1% formic acid in water as the aqueous solvent but cocaine and norcocaine were still not resolvable, despite the ion pairing capabilities of ammonium formate.
This article has not been copyedited and formatted. The final version may differ from this version. Since cocaine and norcocaine could not be separated on the basis of stationary phase selectivity, it was necessary to utilize a column with smaller particle size and thus, higher separation efficiency and improved resolution. There have been reports in the literature of the use of ultra performance liquid chromatography (UPLC) columns in conventional HPLC systems (Cho et al., 2009; Loboda et al., 2000; Woodruff and Pereira, September 2, 2005) . When used at flow rates lower than the optimum, the back pressure generated in the system stays within the limits of the HPLC plumbing, yet large improvements in chromatographic resolution can be achieved. Our final conditions using a Thermo Hypersil Gold column allowed cocaine and its three metabolites analyzed in this study to be retained and resolved well (Figure 4 ), and yielded linear calibration curves ( Figure 5 ).
In vivo results obtained by analyzing plasma samples with this method supported the in vitro data; both demonstrating that DM-CocE was effective at hydrolyzing cocaine and norcocaine, but not benzoylecgonine. The in vivo concentrations of cocaine and norcocaine well illustrate the loss of DM-CocE activity over time. After rapid elimination of cocaine to levels below the quantification limit, the plasma concentrations of both these molecules begin to increase after 20 to 40 minutes post-cocaine injection. We have previously shown that the concentration of CocE in the serum of mice and rats decreases rapidly over time with a half-life of about 1-2 hours Brim et al., In Preperation) . Taken together, these data suggest that this may also be occurring with DM-CocE, and loss of DM-CocE from the circulation likely leads to the reduction in the rate of cocaine elimination. At the reduced removal rate, more cocaine can be found in this compartment, as the return to equilibrium of cocaine is established by redistribution throughout the body. A full kinetic profile of the DMCocE enzyme are to be reported elsewhere (Brim et al., In Preperation) .
This article has not been copyedited and formatted. The final version may differ from this version. A CocE with a longer circulating half-life is needed if all cocaine is to be eliminated at the DM-CocE doses tested here. However, the levels of cocaine that redistribute into the plasma 50 minutes after DM-CocE administration only range from 13.7-92.4 nM, a level that is not toxic and far lower than that observed in recreational cocaine users (Couper and Logan, 2004) .
Attempts to prolong the circulating half-time of CocE through modification by polyethylene glycol polymers (PEGs) are currently being pursued (Narasimhan et al., Submitted) .
We have demonstrated that DM-CocE is able to hydrolyze not only cocaine, but the active and dangerous cocaine metabolites norcocaine and cocaethylene using an LC-MS/MS method to simultaneously quantify cocaine and three of its major metabolites in rat plasma.
Reduction in physiologically active levels of norcocaine and cocaethylene along with the parent molecule gives CocE a property not seen with engineered human butyrylcholinesterases Gao and Brimijoin, 2004; Gao et al., 2008; Pan et al., 2005) and further strengthens the pre-clinical evidence that CocE may be an effective treatment for cocaine toxicity in humans.
This article has not been copyedited and formatted. The final version may differ from this version. Cocaine is rapidly converted into several main metabolites. Human liver carboxylesterase-1 de-methylates 40-45% of cocaine to benzoylecgonine. hCE-1 also catalyzes the conversion of cocaine into the more potent metabolite cocaethylene when alcohol is present. Liver P450 CYP3A4 n-demethylates about 5-10% of cocaine to norcocaine. Serum butyrylcholinesterase (K m =14 µM, k cat =3.9 min -1 (Xie et al., 1999) ) hydrolyzes 40-45% of cocaine into ecgonine methyl ester and benzoic acid. DMCocE also catalyzes this reaction with a faster rate (K m =14 µM, k cat =1432 min -1 ). DM-CocE hydrolyzes the hydrolysis of norcocaine to norecgonine methyl ester and benzoic acid (K m =29 µM, k cat =1307 min -1 ), as well as cocaethylene to ecgonine ethyl ester and benzoic acid (K m =19 µM, k cat =1099 min -1 ).
Figure 3. Hydrolysis of cocaine metabolites by DM-CocE. DM-CocE can hydrolyze the active cocaine metabolites cocaethylene and norcocaine but cannot hydrolyze benzoylecgonine, as determined by the spectrophotometric cocaine hydrolysis assay. Benzoylecgonine was not hydrolyzed, therefore no data is reported in B-D. A Michaelis-Menten saturation curves of DM-CocE hydrolysis of cocaine, compared to the three major metabolites. B The catalytic efficiency of DM-CocE for cocaethylene and norcocaine is 58 and 45% respectively that of cocaine (p<0.001, Students T-test). C The k cat of DM-CocE for norcocaine was unchanged from the k cat for cocaine. Cocaethylene had a significantly reduced k cat as determined by students T-test (p<0.01). D The K m of DM-CocE for both cocaethylene and norcocaine was significantly elevated above that for cocaine (p<0.05 and p<0.001 respectively). .00 µM calibration standard showing separation of ecgonine methyl ester (EME), benzoylecgonine (BZE), cocaine (COC), and norcocaine (NOR) on a Hypersil Gold UPLC column (50mm x 2.1mm i.d., 1.9 µm particles) using 10 mM ammonium formate pH 4.6 as Solvent A and acetonitrile as Solvent B at a flow rate of 0.45 mL/min. 4 µL aliquots were injected onto the column and compounds were eluted over an 11 minute gradient that began with an initial hold at 2% B for 1 minute, increased to 18% B in the next minute, gradually ramped to 40% B over 8 minutes, and finally increased to 100% B in 1 minute. Selected reaction monitoring was used for compound detection and quantification. The chromatogram was divided into 3 time segments during which only the relevant SRM transitions were scanned. This allowed for more accurate characterization of chromatographic peaks and thus, more precise quantification.
This article has not been copyedited and formatted. The final version may differ from this version. Figure 5 . LC-MS/MS calibration curves for cocaine and cocaine metabolites. Calibration curves were constructed for each compound by calculating the ratios of the LC-MS/MS peak areas of the target compounds to the corresponding deuterium-labeled internal standards, and plotting the ratios as a function of analyte concentration normalized to the concentration of internal standard. Data were fitted to a curve using least squares linear regression analysis with 1/x weighting. The linear range for cocaine (COC), benzoylecgonine (BZE), and ecgonine methyl ester (EME) was 0.0313 µM to 4.00 µM. Due to the extremely low concentrations of norcocaine (NOR) observed in the in vivo studies, the calibration curve was adjusted correspondingly and ranged from 0.00313 µM to 0.400 µM. Regression co-efficients (R 2 ) were all ≥ 0.995 and accuracies typically ranged from 67-130%. Figure 6 . Hydrolysis of cocaine metabolites by DM-CocE in Sprague Dawley rats. 5.6 mg/kg cocaine is injected IV at time 0, followed 10 minutes later by either PBS or 0.32 mg/kg DM-CocE. Blood samples were taken throughout the time course and analyzed by mass spectrometry for cocaine metabolites simultaneously. A Cocaine is rapidly eliminated by DMCocE. The concentration of cocaine rises again at t=40 minutes due to the elimination of DMCocE and redistribution of cocaine. B Benzoylecgonine concentrations are affected by DMCocE, most likely due to binding and sequestration by DM-CocE. Also, the absence of high concentrations of cocaine after 10:45 reduces the substrate for hCE-1 production of benzoylecgonine. C Ecgonine methyl ester concentrations are higher in DM-CocE treated animals (equal to that of the original cocaine concentrations) demonstrating the production of EME by DM-CocE. D Norcocaine is rapidly eliminated by DM-CocE.
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